Foghorn Therapeutics Inc. announced its strategic objectives for 2024. FHD-286. FHD-286 is a potent, selective inhibitor of the BRG1 and BRM sub units of the BAF chromatin remodeling complex where dependency on BRG1/BRM is well-established preclinically with multiple tumor types, including acute myelogenous leukemia (AML)/myelodysplastic syndrome (MDS), non-small cell lung cancer (NSCLC) and prostate cancer.

AML Update. Foghorn commenced a Phase 1 study of FHD-286 in combination with decitabine or low-dosecytarabine (LDAC) in relapsed and/or refractory AML patients, with the first patient dosed during the third quarter of 2023. The first clinical data are expected in the second half of 2024.

TKI Resistance. Differentiated Pipeline Advancement. Foghorn continues to expand its platform and pipeline.

The Company anticipates the potential for six new investigational new drug (IND) applications in the next four years. The Company continues to progress programs for multiple targets that include chromatin remodeling complexes, transcription factors, helicases and other chromatin-related factors. Selective EP300 and Selective CBP programs. Foghorn presented new preclinical data for its EP300 and CBP selective degraders showed potent cellular antiprol proliferation and in vivo tumor growth inhibition in an AR+ enzalutamide prostate in vivo model.

At preclinical efficacious doses, neither the EP300 nor the CBP selective degraders caused thrombocytopenia, a commonly observed safety liability for dual CBP/EP300 inhibitors. Additional preclinical data will be presented in the first half of 2024.